Search

Your search keyword '"Kobayashi, Kokoro"' showing total 22 results
Start Over Author "Kobayashi, Kokoro" Publication Year Range Last 3 years
22 results on '"Kobayashi, Kokoro"'

1. Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)

Author

Iwamoto, Takayuki, Niikura, Naoki, Watanabe, Kenichi, Takeshita, Takashi, Kikawa, Yuichiro, Kobayashi, Kokoro, Iwakuma, Nobutaka, Okamura, Takuho, Kobayashi, Takayuki, Katagiri, Yuriko, Kitada, Masahiro, Tomioka, Nobumoto, Miyoshi, Yasuo, Shigematsu, Hideo, Miyashita, Minoru, Ishiguro, Hiroshi, Masuda, Norikazu, and Saji, Shigehira

Published
2024
Full Text
View/download PDF

2. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

Author

Iwamoto, Takayuki, Niikura, Naoki, Watanabe, Kenichi, Takeshita, Takashi, Kikawa, Yuichiro, Kobayashi, Kokoro, Iwakuma, Nobutaka, Okamura, Takuho, Tada, Hiroshi, Ozaki, Shinji, Okuno, Toshitaka, Toh, Uhi, Yamamoto, Yutaka, Tsuneizumi, Michiko, Ishiguro, Hiroshi, Masuda, Norikazu, and Saji, Shigehira

Published
2024
Full Text
View/download PDF

5. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

Author

Watanabe, Kenichi, Niikura, Naoki, Kikawa, Yuichiro, Oba, Mari, Kobayashi, Kokoro, Tada, Hiroshi, Ozaki, Shinji, Toh, Uhi, Yamamoto, Yutaka, Tsuneizumi, Michiko, Okuno, Toshitaka, Iwakuma, Nobutaka, Takeshita, Takashi, Iwamoto, Takayuki, Ishiguro, Hiroshi, Masuda, Norikazu, and Saji, Shigehira

Published
2023
Full Text
View/download PDF

6. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study

Author

Sawaki, Masataka, Taira, Naruto, Uemura, Yukari, Saito, Tsuyoshi, Baba, Shinichi, Kobayashi, Kokoro, Kawashima, Hiroaki, Tsuneizumi, Michiko, Sagawa, Noriko, Bando, Hiroko, Takahashi, Masato, Yamaguchi, Miki, Takashima, Tsutomu, Nakayama, Takahiro, Kashiwaba, Masahiro, Mizuno, Toshiro, Yamamoto, Yutaka, Iwata, Hiroji, Toyama, Tatsuya, Tsugawa, Koichiro, Kawahara, Takuya, and Mukai, Hirofumi

Published
2022
Full Text
View/download PDF

8. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Author

Ozaki, Yukinori, Aoyama, Yosuke, Masuda, Jun, Inagaki, Lina, Kawai, Saori, Shibayama, Tomoko, Maeda, Tetsuyo, Kurata, Mami, Yoshida, Kazuyo, Saeki, Sumito, Hosonaga, Mari, Fukada, Ippei, Hara, Fumikata, Kobayashi, Takayuki, Kobayashi, Kokoro, Miyake, Satoshi, Takano, Toshimi, Ueno, Takayuki, and Ohno, Shinji

Published
2022
Full Text
View/download PDF

11. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

Author

Iwamoto, Takayuki, primary, Niikura, Naoki, additional, Watanabe, Kenichi, additional, Takeshita, Takashi, additional, Kikawa, Yuichiro, additional, Kobayashi, Kokoro, additional, Iwakuma, Nobutaka, additional, Okamura, Takuho, additional, Tada, Hiroshi, additional, Ozaki, Shinji, additional, Okuno, Toshitaka, additional, Toh, Uhi, additional, Yamamoto, Yutaka, additional, Tsuneizumi, Michiko, additional, Ishiguro, Hiroshi, additional, Masuda, Norikazu, additional, and Saji, Shigehira, additional

Published
2023
Full Text
View/download PDF

12. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice

Author

Nakayama, Izuma, primary, Shinozaki, Eiji, additional, Kawachi, Hiroshi, additional, Sasaki, Takashi, additional, Yunokawa, Mayu, additional, Tomomatsu, Junichi, additional, Yuasa, Takeshi, additional, Kitazono, Satoru, additional, Kobayashi, Kokoro, additional, Hayakawa, Keiko, additional, Ueki, Arisa, additional, Takahashi, Shunji, additional, and Yamaguchi, Kensei, additional

Published
2022
Full Text
View/download PDF

13. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Author

Iwata, Hiroji, primary, Nakamura, Rikiya, additional, Masuda, Norikazu, additional, Yamashita, Toshinari, additional, Yamamoto, Yutaka, additional, Kobayashi, Kokoro, additional, Tsurutani, Junji, additional, Iwasa, Tsutomu, additional, Yonemori, Kan, additional, Tamura, Kenji, additional, Aruga, Tomoyuki, additional, Tokunaga, Eriko, additional, Kaneko, Koji, additional, Lee, Min-Jung, additional, Yuno, Akira, additional, Kawabata, Azusa, additional, Seike, Toshihiro, additional, Kaneda, Ayumi, additional, Nishimura, Yozo, additional, Trepel, Jane B, additional, and Saji, Shigehira, additional

Published
2022
Full Text
View/download PDF

14. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

Author

Watanabe, Kenichi, primary, Niikura, Naoki, additional, Kikawa, Yuichiro, additional, Oba, Mari, additional, Kobayashi, Kokoro, additional, Tada, Hiroshi, additional, Ozaki, Shinji, additional, Toh, Uhi, additional, Yamamoto, Yutaka, additional, Tsuneizumi, Michiko, additional, Okuno, Toshitaka, additional, Iwakuma, Nobutaka, additional, Takeshita, Takashi, additional, Iwamoto, Takayuki, additional, Ishiguro, Hiroshi, additional, Masuda, Norikazu, additional, and Saji, Shigehira, additional

Published
2022
Full Text
View/download PDF

15. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: a propensity score-adjusted analysis of a prospective cohort study

Author

Sawaki, Masataka, primary, Taira, Naruto, additional, Uemura, Yukari, additional, Saito, Tsuyoshi, additional, Baba, Shinichi, additional, Kobayashi, Kokoro, additional, Kawashima, Hiroaki, additional, Tsuneizumi, Michiko, additional, Sagawa, Noriko, additional, Bando, Hiroko, additional, Takahashi, Masato, additional, Yamaguchi, Miki, additional, Takashima, Tsutomu, additional, Nakayama, Takahiro, additional, Kashiwaba, Masahiro, additional, Mizuno, Toshiro, additional, Yamamoto, Yutaka, additional, Iwata, Hiroji, additional, Toyama, Tatsuya, additional, Tsugawa, Koichiro, additional, Kawahara, Takuya, additional, and Mukai, Hirofumi, additional

Published
2022
Full Text
View/download PDF

16. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)

Author

Saji, Shigehira, primary, Ohsumi, Shozo, additional, Ito, Mitsuya, additional, Hayashi, Naoki, additional, Kobayashi, Kokoro, additional, Masuda, Norikazu, additional, Niikura, Naoki, additional, Yamashita, Toshinari, additional, Kiyama, Keiichiro, additional, Hasegawa, Ayumi, additional, Nakagawa, Shizuka, additional, and Hattori, Masaya, additional

Published
2022
Full Text
View/download PDF

17. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

Author

Masuda, Norikazu, primary, Ono, Makiko, additional, Mukohara, Toru, additional, Yasojima, Hiroyuki, additional, Shimoi, Tatsunori, additional, Kobayashi, Kokoro, additional, Harano, Kenichi, additional, Mizutani, Makiko, additional, Tanioka, Maki, additional, Takahashi, Shunji, additional, Kogawa, Takahiro, additional, Suzuki, Takuya, additional, Okumura, Shiori, additional, Takase, Takao, additional, Nagai, Reiko, additional, Semba, Taro, additional, Zhao, Zi-Ming, additional, Ren, Min, additional, and Yonemori, Kan, additional

Published
2022
Full Text
View/download PDF

18. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice.

Author

Nakayama, Izuma, Shinozaki, Eiji, Kawachi, Hiroshi, Sasaki, Takashi, Yunokawa, Mayu, Tomomatsu, Junichi, Yuasa, Takeshi, Kitazono, Satoru, Kobayashi, Kokoro, Hayakawa, Keiko, Ueki, Arisa, Takahashi, Shunji, and Yamaguchi, Kensei

Subjects
HEREDITARY nonpolyposis colorectal cancer, MICROSATELLITE repeats, IMMUNE checkpoint inhibitors, DNA mismatch repair, TURNAROUND time, TREATMENT delay (Medicine)
Abstract

Background: In Japan, microsatellite instability (MSI) testing for solid tumors was introduced in clinical practice in December 2018. Although immune checkpoint inhibitors (ICIs) are established standards of care for patients with MSI‐high tumors, the status of implementing MSI testing in clinical practice remains unclear. Methods: We retrospectively reviewed the medical records of patients with solid tumors who underwent MSI testing between January 2019 and December 2020 at our institution. Results: In total, 1,052 MSI tests were performed in 1,047 patients. Regardless of specimen volume and condition, the MSI status was successfully determined in 1,041 (99.0%) tests, encompassing 27 tumor types (microsatellite stable [MSS] or MSI‐low: n = 991 [95.2%] and MSI‐high: n = 50 [4.8%]). Patients whose specimens were fixed with 20% neutral buffered formalin (NBF) and who had specimens with prolonged storage (98.4% and 95.4%) showed lower success rates than those whose specimens were fixed with 10% NBF and who had specimens with nonprolonged storage (100.0% and 99.6%), respectively. The prolonged turnaround time (TAT) in MSI‐high cases (median TAT: 24 days) was a critical issue that directly resulted in treatment delay. Of the 50 patients with MSI‐high tumors, 24 (48.0%) received ICIs and 34 (68.0%) were referred to the Department of Clinical Genetic Oncology where 6 (12.0%) patients were diagnosed with Lynch syndrome. Conclusions: MSI testing was successfully performed for various types of tumors and specimens in clinical practice. Our study results identified certain issues associated with the clinical implementation of MSI testing, including optimal specimen selection, extended TAT in MSI‐high cases, and awareness of hereditary tumors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

Author

Chin, Yoon Ming, primary, Shibayama, Tomoko, additional, Chan, Hiu Ting, additional, Otaki, Masumi, additional, Hara, Fumikata, additional, Kobayashi, Takayuki, additional, Kobayashi, Kokoro, additional, Hosonaga, Mari, additional, Fukada, Ippei, additional, Inagaki, Lina, additional, Ono, Makiko, additional, Ito, Yoshinori, additional, Takahashi, Shunji, additional, Ohno, Shinji, additional, Ueno, Takayuki, additional, Nakamura, Yusuke, additional, and Low, Siew‐Kee, additional

Published
2022
Full Text
View/download PDF

20. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.

Author

Iwata, Hiroji, Nakamura, Rikiya, Masuda, Norikazu, Yamashita, Toshinari, Yamamoto, Yutaka, Kobayashi, Kokoro, Tsurutani, Junji, Iwasa, Tsutomu, Yonemori, Kan, Tamura, Kenji, Aruga, Tomoyuki, Tokunaga, Eriko, Kaneko, Koji, Lee, Min-Jung, Yuno, Akira, Kawabata, Azusa, Seike, Toshihiro, Kaneda, Ayumi, Nishimura, Yozo, and Trepel, Jane B

Published
2023
Full Text
View/download PDF

21. EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase...

Author

Iwata, Hiroji, Niikura, Naoki, Sueki, Hirohiko, Aruga, Tomoyuki, Mukohara, Toru, Kobayashi, Kokoro, Yasojima, Hiroyuki, Nakayama, Takahiro, Toyama, Tatsuya, Ishida, Takanori, Yamashita, Toshinari, Takahashi, Masato, Fujii, Takaaki, El-Hashimy, Mona, Miller, Michelle Kristine, and Kurihara, Ryohei

Published
2023
Full Text
View/download PDF

22. Clinical Experience with Simultaneous Mixed Infusion of Trastuzumab and Pertuzumab in the Neo-Peaks Study (JBCRG-20 Sub-Study).

Author

Bando H, Yasojima H, Ishida K, Kobayashi K, Kasai H, Kashiwaba M, Ohno S, Morita S, Toi M, and Masuda N

Subjects
Humans, Middle Aged, Adult, Aged, Female, Receptor, ErbB-2, Infusions, Intravenous, Trastuzumab administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms drug therapy
Abstract

Dual human epidermal growth factor receptor 2(HER2)blockade with trastuzumab(H)and pertuzumab(P)combined with docetaxel and carboplatin(TCb)is a standard neoadjuvant therapy for HER2-positive breast cancer patients. We conducted this sub-study using data from the investigator-initiated randomized phase 2 JBCRG-20(Neo-peaks)study to evaluate the safety of simultaneous mixed HP infusion in Japanese patients, as there have been no data to date. A total of 204 patients in groups A-C received TCbHP, TCbHP followed by trastuzumab emtansine(T-DM1)+P, and T-DM1+P, respectively. Of the 103 patients in groups A and B who received H and P by sequential infusion in cycle 1, the 17(median age 59; range 29-69 years)who did not experience an infusion reaction(IF)received these agents as a mixed, single-bag infusion from cycle 2 onwards. No cases of IF were observed, thus 71 mixed doses were safely administered. Administration time was reduced to 60 min from cycle 3 onwards. Furthermore, in the group B patients, mixed HP infusion did not affect their subsequent treatment(i. e. 4 cycles of T-DM1+P). Simultaneous administration of H and P enables a reduced administration time, which would benefit both patients and healthcare providers.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results